September 25, 2015.
Indian drugmakers are resisting calls from the US for tighter intellectual property (IP) laws in the country. The Economic Times reports that the Indian Pharmaceutical Alliance (IPA) wrote to industry minister Nirmala Sitharaman on Wednesday - just ahead of Prime Minister Narendra Modi's visit to the US - to state that tighter IP laws will hurt the domestic industry and impede consumers' access to affordable healthcare. Orrin Hatch and Ron Wyden of the Senate Committee on Finance, and Paul Ryan and Sandy Levin of the House Committee on Ways and Means have expressed concerns about India's "insufficient respect for and enforcement of patents, most notably relating to biopharmaceuticals". They identified the trade and investment relationship as a "top priority" ahead of the September 22 inaugural meeting of the US-India Strategic and Commercial Dialogue. But IPA secretary general DG Shah said that what the US is demanding of India exceeds the US's own regulations. "The USA is pressurising India to provide what is not in their own law," Shah wrote to Sitharaman.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.